Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?
Lynparza looks set to add a third tumour type to its label, strengthening the grip of Astrazeneca and Merck & Co on the Parp inhibitor market.
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.